Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a novel missense mutation c.1360G>C (p.Ala454Pro) in the MBTPS2 gene was identified in a boy with typical IFAP syndrome and severe atopic features, although no phenotype/genotype correlation was established.

This review discusses advances in molecular biology and genetics related to androgenetic alopecia and reports no new clinical results.

This article discusses androgenetic alopecia, emphasizing its prevalence, characteristics, and the importance of prompt diagnosis and treatment but reports no new clinical results.

This study reports conflicting evidence on whether GLP-1 receptor agonists are associated with various forms of alopecia, suggesting dermatology practitioners should consider monitoring and counseling patients using these medications.

This article reviews the classification history of androgenic alopecia and highlights the need for further research to find effective hair growth medications.

This pilot study suggests injecting platelet-derived growth factors into the scalp may offer some clinical benefits for androgenetic alopecia, though further randomized trials are needed for confirmation.

In this study, the researchers discovered that specific polyamine depletion enhances stemness in hair follicle stem cells through a mechanism independent of mRNA translation.

The document explains how hair loss patterns in men and women, known as Androgenetic alopecia, are classified using the Hamilton-Norwood system for men and the Ludwig grade system for women.

This study identified TGFβ-2 as a potential driver of progenitor cell loss in hair follicles from early androgenetic alopecia scalps, suggesting its role in the condition's molecular disturbances.

This chapter discusses procedural therapies like platelet-rich plasma and low-level light therapy for androgenetic alopecia, but reports no new clinical findings.

This study found that 4-aminopyridine, a potassium channel blocker, greatly improves skin wound healing by accelerating wound closure, enhancing tissue regeneration, and promoting hair follicle neogenesis.

This article reviews current diagnostic and treatment approaches for androgenetic alopecia but reports no new results, focusing on its progression and medical management options.

This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study of photobiomodulation therapy devices for androgenetic alopecia found variable improvements in hair grade across different skin types and devices, suggesting a need for larger, more comprehensive trials.

This paper discusses the potential of PSA doubling time after radical prostatectomy to predict overall survival but reports no new results.

This study found that platelet-rich plasma significantly increased hair density and anagen hair proportions in androgenetic alopecia patients, suggesting potential as an adjuvant therapy.

The study found that women with hyperandrogenic PCOS have higher levels of AKT1 and AKT2 proteins in their cells, which may lead to cell dysfunction.

This study found that androgen/androgen receptor signaling accelerates premature senescence in dermal papilla cells, highlighting a potential target for treating androgenetic alopecia.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.

This review discusses caffeine's potential role in treating androgenetic alopecia by counteracting DHT effects on hair follicles and enhancing cell proliferation, but reports no new clinical results.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

In this study, several dermoscopic features such as hair diameter diversity, brown peripilar sign, and focal atrichia were frequently observed in both male and female androgenetic alopecia patients, highlighting these as potential AGA indicators.

This study showed that androgenetic alopecia independently predicted higher mortality from diabetes and heart disease in both men and women, with increased rates in individuals with moderate or severe AGA.

In this study, researchers used an integrated in silico approach to demonstrate that Polygonum multiflorum combats androgenetic alopecia via anthraquinone emodin, which targets PI3K catalytic subunits differently from traditional antiandrogenic treatments, showing potential as a novel therapeutic strategy.

This study found that several compounds from Yangxue Shengfa capsule may promote hair growth by enhancing cell proliferation in vitro, suggesting potential use in treating androgenetic alopecia.

This study found that a bioorthogonal microneedle patch delivering AAV-aFGF effectively improved hair follicle regeneration and sustained hair growth in murine alopecia models compared to other methods.

In this study, iL-PRF injections produced significantly better clinical scores for androgenetic alopecia patients compared to controls, especially in those with more severe baseline conditions.

This study found that polyamine levels in hair samples differ between androgenic alopecia and alopecia areata, suggesting potential non-invasive biomarkers to distinguish between these hair loss conditions.